Nicotine injections into the ventral tegmental area increase locomotion and Fos-like immunoreactivity in the nucleus accumbens of the rat.
Systemic administration of nicotine has been shown to increase locomotor activity in rats, an effect which is enhanced by chronic pretreatment with the drug. Furthermore, administration of nicotine either systemically, or locally within the ventral tegmental area (VTA), increases extracellular levels of dopamine (DA) in the nucleus accumbens (NAc). In the present study, we examined the effect of local, bilateral injections into the VTA of nicotine (0.02, 0.2, 2.0 and 8.0 micrograms/0.5 microliter/side) on locomotor activity of rats in an open field. Nicotine (8.0 micrograms/side) significantly increased forward locomotion within 20 min after injection, whereas rearing was not affected. The stimulatory effect of locally applied nicotine was completely blocked by pretreatment with mecamylamine (1.0 mg/kg, s.c.). Repeated intra-tegmental injections of a subthreshold dose of nicotine (2.0 micrograms/side every 2 days), gradually increased locomotion, compared to the effect of acute intra-tegmental administration or control injections of saline, after the fifth and sixth injection. The effects of intra-tegmental injections of nicotine were further investigated on cells in several target areas for the VTA-DA neurons through determination of c-fos expression by means of Fos immunohistochemistry. Intra-tegmental injections of nicotine (8.0 micrograms/side) increased Fos-like immunoreactivity in the NAc, but did not affect the number of Fos-positive nuclei in the medial prefrontal cortex or in the dorsolateral striatum. The increase in accumbal Fos-like immunoreactivity was attenuated by pretreatment with mecamylamine (1.0 mg/kg, s.c.). Our data demonstrate that locomotor activating effects similar to those evoked by systemically administered nicotine, including behavioral sensitization, can be produced by intra-tegmental nicotine administration. Moreover, such local VTA administration of the drug was found to significantly affect neurons within DA target areas. Our findings support the notion that the effects of systemically administered nicotine in mesolimbic target areas are largely dependent on stimulation of nicotinic receptors in the VTA.
Panagis
G
G
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Nisell
M
M
Nomikos
G G
GG
Chergui
K
K
Svensson
T H
TH
D000818:Animals; D004298:Dopamine / Q000378:metabolism; D005731:Ganglionic Stimulants / Q000494:pharmacology*; D007150:Immunohistochemistry; D007267:Injections; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects*; D009411:Nerve Endings / Q000378:metabolism; D009538:Nicotine / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000494:pharmacology; D009714:Nucleus Accumbens / Q000378:metabolism*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013681:Tegmentum Mesencephali / Q000502:physiology*
D005731:Ganglionic Stimulants; D018733:Nicotinic Antagonists; D016760:Proto-Oncogene Proteins c-fos; D008464:Mecamylamine; D009538:Nicotine; D004298:Dopamine